Mobocertinib
Exkivity · EGFR exon20 TKI
Diarrhea-driven prerenal AKI; QT prolongation.
Gilotrif · AFA
EGFR TKI · approved 2013 · 8 citations · FAERS AKI reporting ROR 1.45 (95% CI 1.19–1.76, 101 AKI reports)
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
An irreversible pan-ErbB TKI whose main renal risk is dehydration-driven prerenal AKI from severe diarrhea, plus class hypomagnesemia.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Diarrhea is very common with afatinib (the dominant class toxicity, all-grade in the large majority and grade >=3 in roughly 10-15% in LUX-Lung trials), and the consequent dehydration can precipitate prerenal AKI. Pharmacovigilance data identify afatinib as carrying the strongest renal-failure/AKI signal among EGFR agents, frequently co-reported with diarrhea; trial-based renal incidence is not separately quantified.Source: Crosnier et al., Cancers 2021
Days to weeks after starting, tracking the onset and severity of diarrhea (often within the first cycles).
Distilled from: “Days to weeks after starting therapy, tracking with the onset and severity of diarrhea (often within the first cycles).”
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Direct death of tubular epithelial cells — the dose-limiting lesion of the platinums and zoledronate.
Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).
Tap a signature to trace where it strikes the nephron.
Functional / pre-renal — reduced perfusion upstream of the nephron; no single structural segment is injured.
Prerenal / Hemodynamic AKI: functional / pre-renal, no single structural segment injured.
Prerenal / Hemodynamic AKI
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Irreversible inhibitor of the ErbB family (EGFR/HER1, HER2, HER4) tyrosine kinases, covalently blocking signaling in EGFR-mutant tumors and overcoming some resistance. Used for EGFR-mutant non-small cell lung cancer, including selected uncommon mutations.
Class-level context for the major non-renal toxicities of the EGFR TKI class.
Dermatologic
Rash, HFS, SJS/TEN, vitiligo
Gastrointestinal
Diarrhea, colitis, mucositis, perforation
Pulmonary
Pneumonitis, ILD, effusions, hypertension
6 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.
Quoted verbatim from this agent's current FDA label (Sep 2026) — not paraphrased or interpreted. Full label on DailyMed .
Renal impairment — from the label
Patients with severe renal impairment have a higher exposure to afatinib than patients with normal renal function. Administer afatinib at a starting dose of 30 mg once daily in patients with severe renal impairment (eGFR 15 to 29 mL/min/1.73 m 2 as determined by Modification of Diet in Renal Disease formula) [see Dosage and Administration ( 2.4 ), Clinical Pharmacology ( 12.3 ) ]. Adjustments to the starting dose of afatinib are not necessary in patients with mild or moderate renal impairment (eGFR 30 to 89 mL/min /1.73 m 2 ). Afatinib has not been studied in patients with eGFR <15 mL/min/1.73 m 2 or on dialysis.
Kidney rows of the label's dosage tables
None of the newest openFDA labels for this product carries a dosage table. The label's prose can still give kidney instructions.
Everything below is FAERS — adverse events someone chose to report, about 6,622 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Reported with a death outcome
1,475 of 6,622 reports
Reported with hospitalization
2,095 of 6,622 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial · 630 of the 6,622 reports predate 2015 and are not drawn.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Afatinib sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Exkivity · EGFR exon20 TKI
Diarrhea-driven prerenal AKI; QT prolongation.
Trisenox · Differentiating agent
Differentiation syndrome; QT prolongation.
Idhifa · IDH2 inhibitor
Differentiation syndrome and tumor lysis.
Tibsovo · IDH1 inhibitor
Differentiation syndrome → AKI; tumor lysis.
Mektovi · MEK inhibitor
Creatinine rise; rhabdomyolysis reports.
Koselugo · MEK inhibitor
Creatinine rise in neurofibromatosis.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.
The leading contributors to Afatinib’s clinical kidney literature on PubMed, ranked by a blend of publication volume and citation impact — filtered toward clinical work via the PubMed Humans heading and clinical publication types (trials, cohorts, case reports, guidelines, reviews). Names link to that author’s work on Afatinib; the PMIDs beside each name are up to three of their most recent papers on it, not the full count.
Ranked by a 50/50 blend of publication volume and a position-weighted, capped Relative Citation Ratio (NIH iCite) on this agent’s renal literature; the citation count shown is the raw total, not the ranking score — counted over the 14 clinical records among all 21 PubMed matches, so counts are within-sample — bibliometric context, not an endorsement or a measure of clinical authority.